Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.2c01767 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Baljinder Singh und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States. Hauptthemen laut MEDLINE: Trypanosomiasis, African, Trypanocidal Agents, Trypanosoma brucei brucei. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
The carbazole CBL0137 (1) is a lead for drug development against human African trypanosomiasis (HAT), a disease caused by Trypanosoma brucei. To advance 1 as a candidate drug, we synthesized new analogs that were evaluated for the physicochemical properties, antitrypanosome potency, selectivity against human cells, metabolism in microsomes or hepatocytes, and efflux ratios. Structure-activity/property analyses of analogs revealed eight new compounds with higher or equivalent selectivity indices (5j, 5t, 5v, 5w, 5y, 8d, 13i, and 22e). Based on the overall compound profiles, compounds 5v and 5w were selected for assessment in a mouse model of HAT; while 5v demonstrated a lead-like profile for HAT drug development, 5w showed a lack of efficacy. Lessons from these studies will inform further optimization of carbazoles for HAT and other indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States.
- Department of Molecular and Cellular Biology, Kennesaw State University, Kennesaw, Georgia 30144, United States.
- Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia 30602, United States.
- Incuron Inc., Buffalo, New York 14203, United States.
ORCID-Profile: Baljinder Singh, Pradip K Gadekar, Carlos E Sanz-Rodriguez, Michael P Pollastri
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Singh, B., Sharma, A., Gunaganti, N., Rivers, M., Gadekar, P. K., Greene, B., Chichioco, M., Sanz-Rodriguez, C. E., Fu, C., LeBlanc, C., Burchfield, E., Sharif, N., Hoffman, B., Kumar, G., Purmal, A., Mensa-Wilmot, K., & Pollastri, M. P. (2023). Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01767
Vancouver
Singh B, Sharma A, Gunaganti N, Rivers M, Gadekar PK, Greene B, et al. Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01767
BibTeX
@article{Singh2023,
author = {Singh, Baljinder and Sharma, Amrita and Gunaganti, Naresh and Rivers, Mitch and Gadekar, Pradip K and Greene, Brady and Chichioco, Michael and Sanz-Rodriguez, Carlos E and Fu, Courtney and LeBlanc, Catherine and Burchfield, Erin and Sharif, Nyle and Hoffman, Benjamin and Kumar, Gaurav and Purmal, Andrei and Mensa-Wilmot, Kojo and Pollastri, Michael P},
title = {Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.2c01767}
}
EUVIMED